Clinical study on Qianggan Capsules combined with tenofovir alafenamide in treatment of chronic hepatitis B with poor response to entecavir
Objective To investigate the clinical efficacy of Qianggan Capsules combined with Tenofovir alafenamide Fumarate Tablets in treatment of chronic hepatitis B with poor response to entecavir.Methods Patients(97 cases)with chronic hepatitis B with poor response to entecavir in Liuzhou People's Hospital from March 2020 to February 2021 were divided into the control group(48 cases)and the treatment group(49 cases)according to random number tablet method.Patients in the control group were po administered with Tenofovir alafenamide Fumarate Tablets,1 tablet/time,once daily.Patients in the treatment group were po administered with Qianggan Capsules on the basis of the control group,5 grains/time,twice daily,stop for 1 day every 6 days,with 8 weeks as one course of treatment,stopping for 1 week before proceeding to the second course of treatment.Patients in two groups were treated for 24 weeks.After treatment,the clinical efficacies were evaluated,and HBV-DNA negative conversion rate and ALT normalizing rate,liver fibrosis indexes,liver function indexes,serum indicators in two groups were compared.Results After treatment,the total effective rate of the treatment group(91.84％)was higher than that of the control group(66.67％)(P<0.05).After treatment,HBV-DNA conversion rate and ALT normalization rate in the treatment group were higher than those in the control group(P<0.05).After treatment,the levels of HA,LN,PC Ⅲ,Ⅳ-C,TBIL,ALT,and AST in two groups were decreased(P<0.05),and the levels of HA,LN,PC Ⅲ,Ⅳ-C,TBIL,ALT,and AST in the treatment group were lower than those in the control group(P<0.05).After treatment,the serum levels of PDGF-BB and TGF-β1 in two groups decreased(P<0.05),and the serum levels of PDGF-BB and TGF-β1 in the treatment group were lower than those in the control group(P<0.05).Conclusion Qianggan Capsules combined with Tenofovir alafenamide Fumarate Tablets of chronic hepatitis B with poor response to entecavir can effectively improve liver function in patients,inhibit liver fibrosis,and regulate serum levels of PDGF-BB and TGF-β1.
Qianggan CapsulesTenofovir alafenamide Fumarate Tabletschronic hepatitis B with poor response to entecavirTBILHBV-DNA negative conversion ratePDGF-BBTGF-β1
NETL
NSTL
万方数据
维普
